8. Huntington disease Clinical trials / Disease details
Clinical trials : 229 / Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01411163 (ClinicalTrials.gov) | April 2010 | 4/8/2011 | Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability | Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability | Huntington's Disease | Drug: Creatine monohydrate | Massachusetts General Hospital | National Institutes of Health (NIH) | Completed | 26 Years | N/A | Both | 24 | Phase 2 | United States |
| 2 | NCT00712426 (ClinicalTrials.gov) | September 2009 | 8/7/2008 | Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) | Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) | Huntington's Disease | Drug: Creatine Monohydrate;Drug: Placebo | Massachusetts General Hospital | University of Rochester;National Center for Complementary and Integrative Health (NCCIH) | Terminated | 18 Years | N/A | Both | 553 | Phase 3 | United States;Australia;Canada;New Zealand |
| 3 | NCT01411150 (ClinicalTrials.gov) | May 2009 | 4/8/2011 | Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study | Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study | Huntington's Disease | Drug: Creatine Monohydrate | Massachusetts General Hospital | National Institutes of Health (NIH) | Completed | 26 Years | N/A | Both | 38 | Phase 2 | United States |
| 4 | NCT00592995 (ClinicalTrials.gov) | December 2007 | 28/12/2007 | Creatine Safety and Tolerability in Premanifest HD: PRECREST | Creatine Safety and Tolerability in Premanifest HD: PRECREST | Huntington Disease | Drug: Creatine monohydrate;Drug: Placebo | Massachusetts General Hospital | NULL | Completed | 26 Years | N/A | Both | 64 | Phase 2 | United States |
| 5 | NCT01412151 (ClinicalTrials.gov) | April 2005 | 5/8/2011 | Creatine Safety & Tolerability in Huntington's Disease | Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HD | Huntington's Disease (HD) | Drug: Creatine monohydrate | Massachusetts General Hospital | NULL | Completed | 18 Years | N/A | All | 10 | Phase 2 | United States |